NuCana plc (NCNA) stock
NCNANasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.86−0.07 (-7.45%)
Close on Nov 16, 2026Market cap $3.59MP/E –Yield –
NuCana r&d expenses
Research and development expenses are spending on new products and technology.
NuCana's R&D Expenses for the twelve months ending Dec 31, 2021 was £36.83M, up 42.2% year over year. For fiscal 2025 it was £12.74M, down 29.3% from the year before. Over ten years it grew 8.5% a year on average. The highest annual figure on record is £36.83M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | £12.74M | -29.3% |
| FY2024 | Dec 31, 2024 | £18.02M | -28.1% |
| FY2023 | Dec 31, 2023 | £25.06M | -31.2% |
| FY2022 | Dec 31, 2022 | £36.43M | -1.1% |
| FY2021 | Dec 31, 2021 | £36.83M | +42.2% |
| FY2020 | Dec 31, 2020 | £25.90M | +31.3% |
| FY2019 | Dec 31, 2019 | £19.73M | +17.1% |
| FY2018 | Dec 31, 2018 | £16.85M | -4.7% |
| FY2017 | Dec 31, 2017 | £17.67M | +123.6% |
| FY2016 | Dec 31, 2016 | £7.90M | +39.8% |
| FY2015 | Dec 31, 2015 | £5.66M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | £2.25M | -64.9% |
| Q2 FY2025 | Jun 30, 2025 | £7.10M | -33.2% |
| Q2 FY2024 | Jun 30, 2024 | £6.77M | -24.5% |
| Q2 FY2023 | Jun 30, 2023 | £3.96M | -53.5% |
| Q2 FY2022 | Jun 30, 2022 | £6.41M | -26.4% |
| Q4 FY2021 | Dec 31, 2021 | £10.63M | +33.2% |
| Q3 FY2021 | Sep 30, 2021 | £8.97M | +46.7% |
| Q2 FY2021 | Jun 30, 2021 | £8.52M | +45.4% |
| Q1 FY2021 | Mar 31, 2021 | £8.71M | +46.6% |
| Q4 FY2020 | Dec 31, 2020 | £7.98M | +54.2% |
| Q3 FY2020 | Sep 30, 2020 | £6.12M | +26.3% |
| Q2 FY2020 | Jun 30, 2020 | £5.86M | +9.5% |
| Q1 FY2020 | Mar 31, 2020 | £5.94M | +36.5% |
| Q4 FY2019 | Dec 31, 2019 | £5.18M | +11.3% |
| Q3 FY2019 | Sep 30, 2019 | £4.85M | +45.4% |
| Q2 FY2019 | Jun 30, 2019 | £5.36M | +3.8% |
| Q1 FY2019 | Mar 31, 2019 | £4.35M | +17.4% |
| Q4 FY2018 | Dec 31, 2018 | £4.65M | +22.1% |
| Q3 FY2018 | Sep 30, 2018 | £3.33M | -67.2% |
| Q2 FY2018 | Jun 30, 2018 | £5.16M | +148.3% |
| Q1 FY2018 | Mar 31, 2018 | £3.71M | – |
| Q4 FY2017 | Dec 31, 2017 | £3.81M | – |
| Q3 FY2017 | Sep 30, 2017 | £10.18M | – |
| Q2 FY2017 | Jun 30, 2017 | £2.08M | – |
See a number that looks wrong?